Paroxysmal Atrial Fibrillation (PAF)

Cardiovascular
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Kardium
KardiumBC - Burnaby
1 program
Globe Pulsed Field SystemN/A1 trial
Active Trials
NCT06973031RecruitingEst. Jun 2028
Abbott
AbbottABBOTT PARK, IL
1 program
Grid X and EnSite X v3.1.1 SoftwareN/A1 trial
Active Trials
NCT07421076Not Yet Recruiting200Est. Jan 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
AbbottGrid X and EnSite X v3.1.1 Software
KardiumGlobe Pulsed Field System

Clinical Trials (2)

Total enrollment: 200 patients across 2 trials

NCT07421076AbbottGrid X and EnSite X v3.1.1 Software

Grid eXplore Mapping Study

Start: Mar 2026Est. completion: Jan 2028200 patients
N/ANot Yet Recruiting
NCT06973031KardiumGlobe Pulsed Field System

A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Start: Jun 2025Est. completion: Jun 2028
N/ARecruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 200 patients
3 companies competing in this space